Antibiotic resistance is one of the biggest threats to global health today. Infections like sepsis colloquially known as “blood poisoning” are becoming harder to treat as antibiotics become less effective with rising resistance. Antibiotic resistance infections already cause at least 25,000 deaths in Europe every year. According to the World Health Organization, new rapid diagnostic solutions for antibiotic susceptibility testing (AST) – microbiology tests determining which antibiotics an infected patient should be treated with – are highly needed in order to reduce misuse and overuse of antibiotics and limit the spread of resistance.
Sepsis is more common than heart attack
Sepsis remains the primary cause of death from infection, despite advances in modern medicine, such as vaccines, antibiotics and acute care.
Sepsis is more common than heart attack, and claims more lives than any cancer. Every 3 seconds someone dies in sepsis.
Sepsis is a global healthcare problem where 30 million people – whereof 6 million infants and small children – are afflicted with sepsis every year. About 20 % of these people do not survive sepsis today.
Rapid AST Diagnostics is vital for surviving sepsis
Time is critical and ~36% of sepsis patients receive inappropriate initial antibiotic treatment (Ref: Tängdén et al. J Antimicrob. Chemother. 2011).
The IVD QuickMIC™ system in development by Gradientech can diagnose bacterial resistance in patients with suspected sepsis in only 2 hours based on bacterial growth. The chance of surviving sepsis decreases dramatically for each hour of inappropriate antibiotic treatment, meaning that blood samples are always highly prioritized in hospital laboratories and that rapid AST diagnostic solutions are therefore highly coveted.